StockNews.com assumed coverage on shares of MediciNova (NASDAQ:MNOV – Get Rating) in a research note issued to investors on Thursday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.
Separately, B. Riley decreased their price target on shares of MediciNova from $11.00 to $6.00 in a report on Monday, January 24th.
MNOV opened at $3.03 on Thursday. The stock has a market cap of $148.60 million, a price-to-earnings ratio of -13.17 and a beta of 1.25. MediciNova has a twelve month low of $2.09 and a twelve month high of $5.09. The company’s 50-day moving average price is $2.51 and its two-hundred day moving average price is $2.92.
About MediciNova (Get Rating)
MediciNova, Inc, a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction.
- Get a free copy of the StockNews.com research report on MediciNova (MNOV)
- OrganiGram’s Turnaround Begins To Blossom
- Three Dividend Stocks With Growth Potential
- Exelon Stock Still Has Extraordinary Upside
- Ross Stores On The Verge Of Major Rally
- Greenbrier Companies Stock has Green in its Future
Receive News & Ratings for MediciNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediciNova and related companies with MarketBeat.com's FREE daily email newsletter.